{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:35:37Z","timestamp":1790678137271,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2019.05.010","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T20:03:20Z","timestamp":1561752200000},"page":"116-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Targeted therapy for malignant melanoma"],"prefix":"10.1016","volume":"46","author":[{"given":"Henrik F","family":"Lorentzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2019.05.010_bib0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_bib0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0025","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_bib0030","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_bib0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.05.010_bib0040","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PPO.0000000000000024","article-title":"A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States","volume":"20","author":"Flaherty","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.coph.2019.05.010_bib0050","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0055","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1152\/physrev.00003.2012","article-title":"Regulation of small GTPases by GEFs, GAPs, and GDIs","volume":"93","author":"Cherfils","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.coph.2019.05.010_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188602","article-title":"Variables that influence BRAF mutation probability: a next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma","volume":"12","author":"Gaiser","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2019.05.010_bib0070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","article-title":"Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma","volume":"72","author":"Kim","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.05.010_bib0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.coph.2019.05.010_sbref0080","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbagen.2018.01.018","article-title":"Melanoma metabolism contributes to the cellular responses to MAPK\/ERK pathway inhibitors","volume":"1862","author":"Marchetti","year":"2018","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.coph.2019.05.010_bib0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.coph.2019.05.010_sbref0090","doi-asserted-by":"crossref","first-page":"78174","DOI":"10.18632\/oncotarget.19836","article-title":"BRAF inhibitors: resistance and the promise of combination treatments for melanoma","volume":"8","author":"Griffin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.coph.2019.05.010_bib0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_bib0100","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdu049","article-title":"Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition","volume":"25","author":"Turajlic","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.coph.2019.05.010_bib0110","first-page":"775","article-title":"Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma","volume":"8","author":"Swaika","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.coph.2019.05.010_bib0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_sbref0120","first-page":"1007","article-title":"BRAF: from discovery to drug resistance","volume":"2","author":"Pilat","year":"2018","journal-title":"J Sarcoma Res"},{"key":"10.1016\/j.coph.2019.05.010_bib0125","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s40265-014-0315-4","article-title":"The biology and clinical development of MEK inhibitors for cancer","volume":"74","author":"Luke","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2019.05.010_bib0130","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3975\/10\/3\/035006","article-title":"MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response","volume":"10","author":"Kocieniewski","year":"2013","journal-title":"Phys Biol"},{"key":"10.1016\/j.coph.2019.05.010_bib0135","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1042\/BST20140129","article-title":"Intrinsic and acquired resistance to MEK1\/2 inhibitors in cancer","volume":"42","author":"Sale","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.coph.2019.05.010_bib0140","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.celrep.2013.08.023","article-title":"Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma","volume":"4","author":"Villanueva","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2019.05.010_sbref0145","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0150","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5361569","article-title":"Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature","volume":"2016","author":"Gencler","year":"2016","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.coph.2019.05.010_bib0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/CMR.0000000000000546","article-title":"Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damage","author":"Kimeswenger","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.coph.2019.05.010_sbref0160","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.1200\/JCO.2017.35.15_suppl.9526","article-title":"Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600\u2013mutant melanoma","volume":"35","author":"Chapman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2019.05.010_sbref0165","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_sbref0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.015","article-title":"Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E\/K-mutant advanced or metastatic melanoma","volume":"109","author":"Robert","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.coph.2019.05.010_bib0180","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.05.010_sbref0185","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ctrv.2019.02.001","article-title":"Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma","volume":"74","author":"Zoratti","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.coph.2019.05.010_bib0195","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.05.010_bib0200","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coph.2019.05.010_bib0205","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919830826","article-title":"Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials","volume":"11","author":"Pelster","year":"2019","journal-title":"Ther Adv Med Oncol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:51:15Z","timestamp":1761461475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218301334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":41,"alternative-id":["S1471489218301334"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2019.05.010","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy for malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2019.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}